Manchester Metropolitan University Receives Award at the Diabetic Foot Study Group Scientific Meeting

People with diabetes use innovative pressure-sensing smart insole system to prevent foot ulcers

Berlin, Germany, September 29, 2018  – The oral presentation titled “Novel Plantar Pressure-Sensing Smart Insoles Reduce Foot Ulcer Incidence in ‘High Risk’ Diabetic Patients: A Longitudinal Study” was awarded the prestigious Paul Wilson Brand Repetitive Stress Award at the 15th annual meeting of the Diabetic Foot Study Group of the EASD (European Association for the Study of Diabetes), held in Berlin, Germany September 28 – 30, 2018.

People with diabetes have newfound hope for preventing the development of harmful foot ulcers which threaten the existence of their limbs. Using the SurroSense Rx®, a smart insole system that provides otherwise absent feedback through a smartwatch, allows these people to detect dangerous pressures on the bottom of their feet.

Led by Neil Reeves, Professor of Musculoskeletal Biomechanics, the research team at Manchester Metropolitan University tested the SurroSense Rx system on clinical trial participants with diabetes who have a high risk of developing foot ulcers and found that it reduced the incidence of foot ulcers. At the end of the 18-month long study, the team discovered there was a 71 per cent reduction in re-ulceration in the group using the early warning system compared to a control group using a non-alerting system.

The work was led by the Manchester Metropolitan University in collaboration with the University of Manchester, the Manchester University NHS Foundation Trust, Lancashire Teaching Hospitals NHS Trust, the University of Miami in the United States, and Orpyx Medical Technologies Inc.

About The Diabetic Foot Study Group (DFSG) Scientific Meeting
The DFSG meeting is a unique event within the area of the diabetic foot because it is a true interdisciplinary collaboration between diabetologists, podiatrists, specialist nurses, orthopedic and vascular surgeons, as well as all other specialists with an interest in diabetic patients with foot problems.

About Orpyx® Medical Technologies Inc.
Founded in 2010, Orpyx Medical Technologies empowers people with diabetes to maintain mobility. Orpyx’s core product line, SurroSense Rx®, helps prevent foot ulcers and limb loss through FDA cleared, advanced foot sensor technology and analytics, delivered in an easy-to use ultra-thin insole. Orpyx’s technology is used by researchers to access clinical-grade plantar pressure measurement data for health and human performance applications. Orpyx is focused on collaborating with stakeholders around the world to achieve a healthcare future that is prevention focused and sustainable in cost. Learn more at www.orpyx.com.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501